Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161239 · ClinicalTrials.gov registry record · NA
LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma
A NA study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT00161239 is a NA study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 64 participants.
The verdict
NCT00161239, a NA study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
Peripheral T cell lymphoma and advanced cutaneous T cell lymphomas are aggressive and refractory diseases that are generally treated with chemotherapy. Despite current treatment modalities, only a subset of patients will be cured by the treatment. In this study, four chemotherapeutic agents (L-asparaginase, Methotrexate, Doxil, and Prednisone) will be administered in a combination regimen for patients with relapsed or refractory Peripheral and/or advanced cutaneous T cell lymphoma. Each one of these individual drugs have been shown to have activity to lymphomas. The objective of the study is to determine if the combination of these chemotherapy agents results in higher response and cure rates in this patient population. This will be a single institutional study which will included 32 patients in the Peripheral T cell lymphoma group and 32 patients in the Cutaneous T cell lymphoma group.
Interventions
- DRUG Doxil, Methotrexate, L-Asparaginase, Prednisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00161239
The ClinicalTrials.gov registry entry for NCT00161239 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxil, Methotrexate, L-Asparaginase, Prednisone is the first listed.
NCT00161239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00161239 about?
NCT00161239 is a clinical study titled "LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma". Peripheral T cell lymphoma and advanced cutaneous T cell lymphomas are aggressive and refractory diseases that are generally treated with chemotherapy. Despite current treatment modalities, only a subset of patients will be cured by the treatment. In this study, four chemotherapeutic agents (L-aspar...
What is the current status of trial NCT00161239?
This trial is currently terminated. It is a NA study. The enrollment target is 64 participants. The study started on 2005-02. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00161239?
The interventions under investigation include: Doxil, Methotrexate, L-Asparaginase, Prednisone (DRUG).
Who is sponsoring clinical trial NCT00161239?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.